The FDA has approved Norditropin FlexPro (somatropin [rDNA origin] injection, from Novo Nordisk), a pre-filled injection pen, for patients with growth hormone disorders. Norditropin FlexPro contains Norditropin, which is indicated in children for growth failure caused by very low or no production of growth hormone and in adults who don't produce enough growth hormone. Norditropin is also approved for the treatment of children who have short stature associated with Noonan syndrome, Turner syndrome, and for treatment of children with short stature born small for gestational age with no catch-up growth by age 2–4 years.
Norditropin FlexPro requires no reconstitution and no loading of cartridges. Norditropin FlexPro is expected to be available in the second quarter of 2010 in 5mg/1.5mL, 10mg/1.5mL and 15mg/1.5mL pens.